Skip to main content

Our Mission

To improve the lives of people impacted by hypoparathyroidism through education, support, research, and advocacy. Learn more and get involved.

NEWS & EVENTS

Unexpected manufacturing disruptions expected as early as November 21, 2020

AZP-3601 is currently in development for the treatment of hypoparathyroidism

Plans move forward with phase 3 PaTHway trial

The study will be conducted at the National Institutes of Health.

OCT 23 - 25. Live informative lectures on HypoPARA with knowledgeable doctors and specialists!